Introduction
High-dose chemotherapy (HDC) and bone marrow transplant (BMT) and, in recent years, autologous peripheral blood stem cell transplant (ASCT) are well recognized treatment options in diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) in a variety of settings. Chemotherapy 1 and growth factors (G-CSF, GM-CSF) have demonstrated their capacity to increase the circulating population of peripheral blood stem cell (PBSC) manyfold. [2] [3] [4] Combining the two approaches has a synergistic effect. 5 ASCT is superior to BMT in terms of quicker recovery from myelosuppression, easier to perform, cheaper and potentially less hazardous. [6] [7] [8] [9] Many mobilization regimens have been reported in the literature but cyclophosphamide (1-7 g/m 2 ) followed by G-CSF is one of the most commonly reported in patients with lymphoma. [10] [11] [12] [13] [14] [15] [16] [17] Lately, other combinations with superior antitumor efficacy have been tried with success. 13, 15, [18] [19] [20] [21] [22] ESHAP 23 (Etoposide 40 mg/m 2 i.v. over 1-3 h, daily for 4 days, solumedrol 500 mg i.v. daily for 4 days, cisplatin 25 mg/m 2 /day i.v. as a continuous infusion over 24 h daily for 4 days and Ara-C 2 Gm/m 2 i.v. over 2-3 h, following completion of Cisplatin on day 5) is a well accepted salvage chemotherapy for patients with DLCL and HD. Limited data is available for ESHAP chemotherapy as a mobilizer. Few available studies had shown that ESHAP can be used safely as a mobilizer regimen. 19, 20, 22 
Materials and methods

Patients
All patients with relapsed or refractory DLCL and HD who had HDC ASCT were identified by the Oncology Data Unit. From 1996 to November 2004, 131 patients with relapsed or refractory DLCL and HD who had received either ESHAP alone or ESHAP alternating with some other salvage chemotherapy regimen such as IMVP-16, IMCCNU, MIME, but ESHAP as mobilization chemotherapy prior to planned ASCT were selected for this analysis. All patients were admitted to the hospital for chemotherapy infusion. Responding DLCL patients and responding or stable HD patients (WHO response criteria) received ESHAP for mobilization of PBSC. Four patients did not mobilize and were excluded from this analysis. These patients had either cyclophosphamide for mobilization or bone marrow harvest for stem cell collection. A total of 127 patients, who had HDC ASCT are included in this analysis. Patients received fixed dose G-CSF (neupogen, Roche Oncology) 300 mg SC twice a day starting 24-36 h after finishing mobilizing ESHAP and continued until the morning of last apheresis. Carmustine, etoposide, cytarabine and melphalan (BEAM) was used as HDC. Stem cell reinfusion was performed on day 0 and G-CSF 300 mg SC twice a day was started from day þ 1 till absolute neutrophil count (ANC) reached X0.5 Â 10 9 /l for 3 days or X1000 Â 10 9 /l for 1 day in most cases.
Apheresis procedure
Daily apheresis using the COBE Spectra BCT, to collect a minimum of 2 Â 10 6 CD34 þ cells/kg body weight (ideally 5 Â 10 6 CD34 þ cells/kg body weight), was initiated when peripheral blood CD34 þ cell count exceeded 20 CD34 þ cells/ml. First apheresis volume was 10 l (patients p70 kg), 12 l (70-95 kg), and 15 l (495 kg). Patients o60 kg often had o9 l due to tolerability. The apheresis product was mixed with the same volume of minimal essential medium containing 20% dimethylsulfoxide and stored at À1961C. Product volume, CFU-GM, CFU-GMME and CFU-E (BFUE) were also recorded.
CD34 enumeration
CD34 enumeration was performed on aliquots of apheresis samples using a single-platform flow cytometric method based on ISHAGE gating strategy as previously described. 24 Briefly, 50 ml of diluted cells were incubated in TRUECOUNTt tubes (BD Biosciences, #340334) containing fluorescence-labeled reference beads with antibodies against CD45-FITC (BD # 347463)/CD34-PE (clone 8G12, BD # 348057) and a viability dye 7-amino actinomycin D (7-AAD) (Coulter # IM-3422). Cells will be lysed with NH 4 Cl. Samples were analyzed on a FACScalibur flow cytometer (BD Biosciences, USA) with a 488-nm argon laser and Cell Quest 3.1 software (BD Biosciences, USA). The number of CD34 þ cells per microliter was calculated using the following formula: Âsample dilution factor CFU-GM, CFU-GMME and CFU-E assays The assay for CFU-Mix, BFU-E and CFU-GM was carried out as described elsewhere. 25 Briefly, MNC were plated in duplicate in MethoCultt H4433 and H4534 media (Stem Cell Technologies, Vancouver, Canada) at a concentration of 10 Â 10 4 /ml. Cultures were incubated at 371C and in 5% CO 2 for 9-14 days, colonies were then scored directly under an inverted microscope and classified as burst-forming units erythroid (BFU-E), CFU-GM and CFU-GMME. A CFU-GM was defined on the basis of its ability to produce at least 40 cells, and CFU-GMME should contain at least 20 cells of GM lineage in close proximity to the erythroid component.
Engraftment evaluation
Engraftment was defined as the first day when ANC of X0.5 Â 10 9 /l was reached (lasting for at least 3 days) after the initial nadir post HDC ASCT. Various definitions are used to describe platelet engraftment; we used the International Bone Marrow Transplant Registry (IBMTR) definition, that is the first day of three consecutive complete blood counts with platelets X20 Â 10 9 /l after the initial nadir post HDC ASCT in the absence of platelet transfusion or day 7 post last platelet transfusion (platelet transfusion þ 7 ), provided that the platelet counts on day þ 7 post transfusion remained X20 Â 10 9 /l. We have also reported the more practically used platelet engraftment definition that is last platelet transfusion þ 1 day provided that the platelet counts on that day remained X20 Â 10 9 /l. Many patients were discharged home and came back to our clinic 5-10 days after last platelet transfusion and at that time platelets were checked. Platelet transfusion threshold was p10 Â 10 9 /l for asymptomatic patients and for febrile patients it was o20 Â 10 9 /l. For few patients with deep venous thrombosis who were receiving heparin infusion, platelets were kept 430 Â 10 9 /l. Statistical analysis SPSS Version 10 was used for statistical analyses. Pearson's correlation (continuous variables) or one-way analyses of variance (ANOVA) (categorical variables) were utilized to determine the significant associations with CD34 þ cells collection. Pairwise comparisons were performed if ANOVA or ANCOVA were significant at the 0.05 level. Univariate regression models was created to investigate the effect of histology and weight on CD34 þ cells collection. Results were considered significant if Po0.05 (two-sided).
Results
A total of 131 consecutive patients, who received ESHAP chemotherapy for mobilization followed by HDC ASCT were included in this analysis. Four patients failed mobilization and were excluded from the analysis. In all, 127 patients with successful mobilization are included in this analysis. Patient's characteristics are shown in Table 1 . The distribution of total number of cycles is shown in Table 1 for patients with DLCL and HD. For patients who receiving CHOP (42 patients) as initial treatment, the distribution was o6 cycles (six patients), six cycles (23 patients), seven cycles (two patients) and eight cycles (11 patients). For patients who received ABVD (48 patients), it was o6 cycles (seven patients), six cycles (22 patients), seven cycles (four patients) and eight cycles (15 patients). Patients who received 'others' have mostly MOPP or COPP or MOPP/ABV chemotherapy, o6 cycles (six patients), six cycles (15 patients), seven cycles (two patients), eight cycles (five patients) and 48 (seven patients).
The dose of G-CSF was 300 mg SC twice a day starting 24-36 h after finishing mobilizing ESHAP in all but three patients (480, 200 and 230 mg SC twice a day).
Autologous stem cell collection
The total number of aphereses performed was 171 in 127 patients. The median day of apheresis from the first day of starting mobilization ESHAP was 14 days (range 12-21 days (P ¼ 0.001). Results of apheresis, CD34 þ cells collection and CFU-GM, CFU-GMME and CFU-E (BFUE) are also shown in Table 2 .
Weight of patients and CD34 þ cells collection As the dose of G-CSF used in this group is different to the conventional weight based dosing, CD34 þ cells collection results for different weight groups and histology are also presented in Tables 3-5 .
Engraftment data
Neutrophil engraftment was 100%. Four patients failed platelet engraftment (platelets o20 Â 10 9 /l by day 30 without transfusion or X20 Â 10 9 /l with transfusion only). Of these, one patient died on day 61 due to treatment related mortality (septic shock post transplant), one patient received the last platelet transfusion on day þ 24 and engrafted on day 31 as per IBMTR definition, one patient with four previous lines of chemo and more than 20 prior chemotherapy cycles engrafted after 2 months and the (10) 13 (11) 25 (20) 70 kg 16 (13) 18 (14) 34 (27) No. of apheresis 1 35 (28) 58 (46) 93 (73) 2 11 (9) 14 (11) 25 (20) 3 3 (2) 5 (4) 8 (6) One patient at 4th and one patient at 5th relapse (% rounded to the nearest full digit, so total may not be 100% in some cases). e Failed to achieve complete remission at the end of planned treatment or progressed during initial treatment (no response, stable disease, partial response, progressive disease at the end of planned treatment). All values are median. fourth patient had progressive disease post HDC ASCT and failed engraftment. This is shown in Table 6 .
Discussion
The optimal way to mobilize stem cells is still under investigation. For patients with non-Hodgkin's lymphoma (NHL) and HD undergoing HDC ASCT, the current standard approach is the use of chemotherapy and G-CSF as a mobilization regimen. Cyclophosphamide (1-7 g/m 2 ) is one of the most common single agent chemotherapy reported for mobilization. Other combinations, such as ESHAP, DHAP and ifosfamide based salvage chemotherapy with superior antitumor activity are also tried with good success. 13, 15, [18] [19] [20] [21] [22] There is a wide range of doses and schedules of G-CSF and other cytokines described in the literature for mobilization. 7, [26] [27] [28] Currently the most common is G-CSF 5-10 mg SC/kg/day.
Stem cell collection may be influenced by multiple factors such as type of lymphoma, age, stage, type and frequency of previous chemotherapy, radiation therapy (XRT), mobilization regimen and type of apheresis machine. [29] [30] [31] [32] [33] [34] Most reports had a very diverse group of patients including HD and low, intermediate and high-grade NHL, acute myelogenous leukemia and even some solid cancers. These patients have diverse characteristics with a wide range of variables. They often had very different pre-salvage chemotherapy exposure and a variety of salvage chemotherapies due to the different nature of their disease. This makes it very difficult to draw a conclusion for a specific disease and CD34 þ cell collection in that disease.
Our data is the largest single institution retrospective data to report the use of ESHAP as mobilization regimen in a very uniform set of patients. Unlike older studies where patients are offered HDC ASCT after multiple chemotherapy regimen failure and extensive pretransplant chemotherapy exposure, our patients reflect the recent trends in DLCL and HD therapy that is, early transplant for relapsed and refractory patients. Only 20 patients (18 with HD) in our study had 48 cycles of chemotherapy prior to the start of mobilization regimen. There is no low grade/ indolent/mantle cell NHL included in our analysis. Our patients have a median age of 26 years at transplant. This is simply a reflection of age distribution of DLCL (median age 48 years for DLCL and 45 years for all NHL) and HD (median age 19 years) in our population. 65% of DLCL and 70% of HD patients are younger than 60 years in this country (recent published data from National Cancer Registry of Kingdom of Saudi Arabia).
Three other studies 19, 20, 35 have also reported the use of ESHAP as a mobilization regimen in NHL and HD. It is difficult to compare our results with other reports due to the difference in patient population, type and dosing of growth factors, stem cell collection technique and the machine used. Petit 19 reported median CD34 þ cell collection of 7.4 Â 10 6 /kg in 22 patients and Watts 20 reported median CD34 þ cell collection of 4.8 Â 10 6 /kg in 78 patients. Both ours and Watts 20 study showed that 470% patients required only one apheresis. Lee et al. Different institutions have different guidelines for the starting time of G-CSF after a specific chemotherapy regimen. The minimum acceptable dose and the duration of G-CSF in this setting in not known. We used fixed dose of G-CSF 300 mg SC twice a day starting 24-36 h after finishing mobilizing ESHAP rather than the standard weight based dosing of 5-10 mg/kg/day. Given the wide range of G-CSF dosing described in the literature 7 and an appropriate CD34 þ cells collection in almost all cases, this fixed dose falls in the middle of different dosing schedules. Given the wide range of equally good dosing, our fixed dose was able to produce a good result even in patients 470 kg. At the same time, it also indicates that most likely lower doses of G-CSF can produce the same results in the same setting.
Our data clearly and convincingly demonstrate that ESHAP þ G-CSF 300 mg SC twice a day starting 24-36 h after finishing mobilizing ESHAP for autologous peripheral blood stem cell mobilization in patients with relapsed or refractory DLCL and HD is appropriate. Fixed dose G-CSF can safely replace weight-based dosing regimen in this setting. Other appropriate dosing and timing of G-CSF in this setting will require more investigation in a uniform set of patients.
